Amanote Research
Register
Sign In
P1.01-112 Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients With EGFRm Advanced NSCLC
Journal of Thoracic Oncology
- United States
doi 10.1016/j.jtho.2018.08.669
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Oncology
Respiratory Medicine
Pulmonary
Date
October 1, 2018
Authors
C. Zhou
Y. Cheng
Y. He
W. Li
H. Zhang
Q. Zhou
B. Wang
C. Liu
S. Ramalingam
A. Walding
M. Saggese
J. Wang
M. Fan
Y. Wu
Publisher
Elsevier BV
Related search
P1.01-60 Preventing and Treating Brain Metastases With Three First-Line EGFR-TKI in Patients With EGFR Mutation Advanced NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Comparison of EGFR-TKI and Chemotherapy in the First-Line Treatment of Advanced EGFR Mutation-Positive NSCLC
Neoplasma
Cancer Research
First-Line Osimertinib in Patients With Treatment-Naive Somatic or Germline EGFR T790M–Mutant Metastatic NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
MA15.03 PD-L1 Expression in Untreated EGFRm Advanced NSCLC and Response to Osimertinib and SoC EGFR-TKIs in the FLAURA Trial
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P2.13-23 Osimertinib Treatment Result of Plasma T790M Positive in Different Clinical Failure Modes After First-Line EGFR TKI for EGFR Mutant NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Switching From First or Second Generation EGFR-TKI to Osimertinib in EGFR Mutation-Positive NSCLC
Lung Cancer Management
P1.01-88 Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFRm-Positive Stage III NSCLC (LAURA)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Osimertinib as First-Line Therapy in Advanced NSCLC: A Profile of Its Use
Drugs and Therapy Perspectives
Pharmacology
First-Line Treatment in NSCLC Harboring EGFR Common Mutations: EGFR TKI in Monotherapy or in Combination With Anti-Vegf?
Expert Review of Anticancer Therapy
Oncology
Pharmacology